Editorial Response: Randomized Trial of Lipid-Based Amphotericin B for Invasive Aspergillosis in Neutropenic Hosts Is an Important Step Forward
Fungal infection is a prominent cause of morbidity and death penic patient who requires multiple antibiotics (many of which among patients compromised by neutropenia, especially those are renally excreted) or nephrotoxins such as cyclosporine A. with acute leukemia and prolonged, therapy-induced bone marIn addition, the constitutional symptoms (fever, rigors) that row aplasia [1 -4] . The significant incidence of documented often accompany AmB administration may confound the pafungal infections, coupled with the high mortality when earliest tient's overall clinical picture and, at times, can be severe manifestations go untreated, supports the use of early and agenough to cause hypotension and bronchospasm. gressive therapy with amphotericin B (AmB) in the manageIn this light, the development of lipid formulations of AmB ment of these cases. Many of these invasive infections are (L-AmB) has been greeted with strong enthusiasm. These prepcommonly caused by Aspergillus, which exhibits significant arations are designed to deliver higher concentrations of drug microbiological and clinical resistance to AmB [4, 5] . At least to sites of active infection and, at the same time, to spare clinically, this intrinsic resistance can be overcome in part by the host from the well-documented AmB-related multiorgan the delivery of high doses of drug.
toxicities (especially renal dysfunction) [2, 6, 7] . NoncomparaInvestigators at several centers have demonstrated that tive studies involving bone marrow and solid organ transplant prompt detection and institution of aggressive fungicidal therrecipients substantiate that L-AmB preparations are more tolerapy with high-dose AmB (1.0 -1.25 mg/[kgrd]) alone or in able and at least as efficacious as traditional AmB, especially combination with 5-flucytosine result in enhanced survival in for candidiasis. cases of infection caused by filamentous organisms such as When used as antifungal prophylaxis during bone marrow Aspergillus and Fusarium species or non -Candida albicans transplantation, L-AmB can suppress fungal colonization and yeasts [1, 3 -5] . The impact of this approach is most clearly reduce the incidence of both presumed and documented fungal seen in documented infections caused by filamentous fungi, in infections. Documentation of the efficacy of L-AmB against which delayed institution of antifungal therapy is associated fusarium infection in the setting of leukemia-associated marrow with a 50% decrease in survival rate, relative to when AmB failure suggests the potential for enhanced efficacy against other therapy is instituted empirically before definitive diagnosis, traditionally AmB-refractory filamentous fungi, for instance, Asoften on the basis of nonspecific clinical findings [1] .
pergillus species and other emerging pathogens [6, 7] . Still, the most efficacious usage of these lipid-modified AmB See article by Ellis et al. on pages 1406 -12.
preparations in the armamentarium of antifungal interventions has yet to be defined. To this end, the EORTC presents in this issue a large, prospective, randomized clinical trial that is the Early institution of AmB therapy has yielded gratifying refirst to compare the therapeutic efficacy of two dosages of sults and has been adopted by many investigators as a practical L-AmB against documented or probable aspergillosis in neutrostandard of care for definitive or presumed fungal infections penic hosts [8] . This is a pioneering effort to obtain biologically (typified by aspergillosis) in the profoundly neutropenic host. and statistically meaningful data before a standard of care is Yet, in retrospect, it is unfortunate that there have been no established -indeed, to use scientific principles as a foundation randomized or controlled studies in this complex clinical setting upon which to determine an optimal management approach. to demonstrate the superiority of aggressive AmB management
The EORTC has conducted this pivotal trial in the subset of over a more traditional and conservative approach to diagnosis compromised patients with definitive (microbiologically docuand therapy.
mented) or probable (clinically and radiographically detected) One obstacle to early and aggressive AmB therapy has been invasive aspergillosis [8] . Such patients are notoriously difficult the knowledge that AmB is not a completely benign drug. Over to study in any trial design, particularly in a randomized fashthe years, however, it has become possible to blunt many of ion. Invasive fungal infections in the neutropenic population the toxicities by maintaining renal perfusion, preventing AmBevade attempts at early diagnosis for several reasons [1 -5] . induced renal artery spasm, and administering agents aimed
The lack of inflammatory effector cells in these patients often at inhibiting inflammatory cytokines. Still, AmB-related renal mutes localizing tissue-specific physical signs, making clinical dysfunction adds a layer of complexity to treating the neutrofindings characteristically nonspecific early in the course of infection. Invasive procedures to definitively establish the diagnosis of systemic infection can further complicate definitive diagnosis. with use of ''anti-Aspergillus'' doses of conventional AmB (1 -1.25 mg/[kgrd]) as a third arm for randomization. Indeed, These problems are compounded by the lack of sensitive laboratory tests providing rapid identification of pathogenic fungi nonliposomal AmB at such doses would serve as a useful standard against which to measure the efficacy of these newer and of generally available methods for fungal drug susceptibility testing.
AmB preparations. Such comparisons are sorely needed, since the only data available regarding L-AmB preparations have Perhaps it is time for industry and government to support the been derived from open-label studies [6, 7] , and direct headdevelopment and application of surrogate biochemical markers to-head comparisons of equivalent doses of conventional AmB (fungal antigens, metabolites, and nucleic acids, for example) and high-dose liposomal preparations have not been performed. for early detection of fungal infection. Radiographic studies
In sum, the EORTC has tackled a number of pivotal issues with CT are useful in the early detection as well as the followsurrounding the management of aggressive fungal infections up of deep-tissue invasion but do not provide absolute or spein the profoundly neutropenic host. Clinical investigation in cific identification of the responsible pathogen [1, 5, 8] . The this setting is particularly challenging, in part because of the epidemiology of fungal infections can be highly variable, as tremendous variability in patient status and in part because well, since aspergillus infections often occur in clusters, with of the inherent difficulties in securing a definitive diagnosis the precipitating factors and therefore the timing of those cluspromptly and accurately. In addition, the EORTC should be ters being difficult to anticipate. Last, these critically ill patients commended for its willingness to include those patients with evince multiple confounding factors, making stratification un-CT abnormalities in the study, because it is in this subgroup manageable both biostatistically and biologically.
of patients that early institution of aggressive antifungal therapy From the data generated, the authors are forced to conclude may make a formative difference in clinical outcome. that more is not necessarily better when it comes to L-AmB.
EORTC investigators have broken new ground with this This counterintuitive finding stands in contradistinction to studstudy and, by so doing, have raised some provocative issues ies demonstrating the enhanced clinical effects of high-dose that need to be addressed if we are to optimize our approaches AmB for the relatively AmB-resistant fungi. However, the apto these critically ill patients. The EORTC has started a new parent paradox might relate to any one of several parameters: generation of studies in the arena of antifungal therapy, and (1) the inherent difficulties in diagnosing the presence and we are likely to be busy addressing the complexities of AmB magnitude of aspergillus infections in the neutropenic host; (2) and aspergillosis for a long time to come. the lack of reliable and reproducible in vitro drug susceptibility testing for Aspergillus (and for filamentous fungi in general); 
